SG11202111450QA - Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments - Google Patents
Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatmentsInfo
- Publication number
- SG11202111450QA SG11202111450QA SG11202111450QA SG11202111450QA SG11202111450QA SG 11202111450Q A SG11202111450Q A SG 11202111450QA SG 11202111450Q A SG11202111450Q A SG 11202111450QA SG 11202111450Q A SG11202111450Q A SG 11202111450QA SG 11202111450Q A SG11202111450Q A SG 11202111450QA
- Authority
- SG
- Singapore
- Prior art keywords
- alkyl
- cancer treatments
- mitochondria targeting
- tpp compounds
- tpp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962834932P | 2019-04-16 | 2019-04-16 | |
| US201962842893P | 2019-05-03 | 2019-05-03 | |
| PCT/US2020/028414 WO2020214754A1 (en) | 2019-04-16 | 2020-04-16 | Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111450QA true SG11202111450QA (en) | 2021-11-29 |
Family
ID=72837603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111450QA SG11202111450QA (en) | 2019-04-16 | 2020-04-16 | Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220211728A1 (en) |
| EP (1) | EP3955935A4 (en) |
| JP (1) | JP2022529949A (en) |
| KR (1) | KR20210152500A (en) |
| CN (1) | CN114025769A (en) |
| CA (1) | CA3136811A1 (en) |
| SG (1) | SG11202111450QA (en) |
| WO (1) | WO2020214754A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230066947A (en) | 2021-11-08 | 2023-05-16 | 현대모비스 주식회사 | Lamp for vehicle |
| WO2023119232A1 (en) * | 2021-12-22 | 2023-06-29 | Lunella Biotech, Inc. | Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2494668T3 (en) * | 2010-04-28 | 2014-09-15 | Alcon Research, Ltd. | Pharmaceutical compositions with phosphonium antimicrobial agents |
| US9801922B2 (en) * | 2011-08-03 | 2017-10-31 | University Of Iowa Research Foundation | Compositions and methods of treating cancer |
| WO2014124384A1 (en) * | 2013-02-08 | 2014-08-14 | University Of Iowa Research Foundation | Compositions and methods for cancer therapy |
| PT2989110T (en) * | 2013-04-24 | 2018-11-15 | Jira Neuzil | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level |
| PL229277B1 (en) * | 2015-07-28 | 2018-06-29 | Centrum Badan Molekularnych I Makromolekularnych Polskiej Akademii Nauk | Medical application of triphenylphosphonium salts |
| IL305316B1 (en) * | 2017-03-15 | 2024-05-01 | Lunella Biotech Inc | Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast |
| EP3612540A1 (en) * | 2017-04-20 | 2020-02-26 | Rising Tide Foundation | Triphenylphosphonium-tethered tetracycyclines for use in treating cancer |
| US11161862B2 (en) * | 2017-04-20 | 2021-11-02 | Oxford University Innovation Limited | Phosphonium-ion tethered tetracycline drugs for treatment of cancer |
| EP3624897A4 (en) * | 2017-05-19 | 2021-07-14 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| WO2019104115A1 (en) * | 2017-11-24 | 2019-05-31 | Lunella Biotech, Inc. | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells |
| US20220365069A1 (en) * | 2019-09-13 | 2022-11-17 | Lunella Biotech, Inc. | Atp-based cell sorting and hyperproliferative cancer stem cells |
-
2020
- 2020-04-16 US US17/604,651 patent/US20220211728A1/en active Pending
- 2020-04-16 KR KR1020217035882A patent/KR20210152500A/en unknown
- 2020-04-16 EP EP20791432.6A patent/EP3955935A4/en active Pending
- 2020-04-16 WO PCT/US2020/028414 patent/WO2020214754A1/en unknown
- 2020-04-16 CN CN202080043979.4A patent/CN114025769A/en active Pending
- 2020-04-16 JP JP2021561710A patent/JP2022529949A/en active Pending
- 2020-04-16 CA CA3136811A patent/CA3136811A1/en active Pending
- 2020-04-16 SG SG11202111450QA patent/SG11202111450QA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3955935A1 (en) | 2022-02-23 |
| KR20210152500A (en) | 2021-12-15 |
| CN114025769A (en) | 2022-02-08 |
| JP2022529949A (en) | 2022-06-27 |
| WO2020214754A1 (en) | 2020-10-22 |
| US20220211728A1 (en) | 2022-07-07 |
| CA3136811A1 (en) | 2020-10-22 |
| EP3955935A4 (en) | 2023-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3463570A4 (en) | Internal ultraviolet therapy | |
| ZA201906613B (en) | Pharmaceutical compositions for combination therapy | |
| BR112017000130A2 (en) | method for mitigating toxicity associated with notch pathway inhibition and cancer treatment method | |
| EP3407978A4 (en) | Combination therapy for treating cancer | |
| IL266012A (en) | Combination therapy for c3 inhibition | |
| EP3285773A4 (en) | Combination therapy for treating cancer | |
| EP3678663A4 (en) | Combination therapy for treating cancer | |
| ZA201905510B (en) | Pharmaceutical compositions for combination therapy | |
| EP3137117A4 (en) | Combination therapies targeting mitochondria for cancer therapy | |
| EP3371201A4 (en) | Conjugated antisense compounds for use in therapy | |
| EP3710039A4 (en) | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway | |
| EP3331558A4 (en) | Combination therapies targeting mitochondrial biogenesis for cancer therapy | |
| EP3737383A4 (en) | Synergistic cancer treatment | |
| IL268416A (en) | Pharmaceutical combinations for treating cancer | |
| GB201818110D0 (en) | Monocytes for cancer targeting | |
| IL282093A (en) | Combination therapy for cancer | |
| EP3411399A4 (en) | Antibody-drug synergism technology for treating diseases | |
| EP3256473A4 (en) | Synergistic cancer treatment | |
| SG11202111450QA (en) | Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments | |
| BR112018012116A2 (en) | intravesical therapy for bladder cancer | |
| EP3630090A4 (en) | Combination therapy for cancer using botanical compositions and enzalutamide | |
| IL256451B (en) | Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor | |
| IL268708B (en) | Pharmaceutical compositions for combination therapy | |
| EP3697947A4 (en) | Accounting for induced fit effects | |
| EP3673907A4 (en) | Pharmaceutical for cancer treatment including ax1 inhibitor as an effective component |